The FDA confirmed that a pause on publishing drug rejection letters is lifted, meaning additional rejection documents will be released in coming weeks after the agency halted the practice in April. The move continues the FDA’s contested transparency push around how review outcomes are communicated to stakeholders, and it follows a period when release activity was temporarily suspended.